An observational study in Hemophagocytic Lymphohistiocytosis, sponsored by Swedish Orphan Biovitrum. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Swedish Orphan Biovitrum · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Lymphohistiocytosis, Hemophagocytic with a site in United States — 11 open to participants now, 19 under way, 1 of them phase 3. Lymphohistiocytosis, Hemophagocytic · United States.
Among the 42 studies in Lymphohistiocytosis, Hemophagocytic with a site in United States, this one is one of 3 that started in 2016, is one of 9 observational ones, and was the 24th registered.
111 studies on the registry are indexed under Lymphohistiocytosis, Hemophagocytic; 41 are open to participants now.
Browse Lymphohistiocytosis, Hemophagocytic studies →11 of the 42 studies in Lymphohistiocytosis, Hemophagocytic with a site in United States are open now. Recruiting first, the newest first:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18–99
Jerry Lee, MD, MSc, MPhil · Sites in United States
Ages 18+
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18–120
University of Alabama at Birmingham · Sites in United States
Electra Therapeutics Inc. · Sites in United States, Austria, Germany and 4 more countries
Ages 6+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 26 Lymphohistiocytosis, Hemophagocytic studies recruiting now, 14 (54%) set no upper age limit and 8 (31%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 23 · Phase 3 6
First in 2000; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 114 across 34 observational studies indexed under Lymphohistiocytosis, Hemophagocytic.
Median enrollment 21 across the 32 interventional studies, 200 across the 9 observational. Of the 21 that completed or were terminated, 19 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 42 have an industry lead sponsor. The 10 most frequent:
Swedish Orphan Biovitrum is the lead sponsor of 82 studies on the registry; 6 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
Swedish Orphan Biovitrum has 9 studies filed under Lymphohistiocytosis, Hemophagocytic — fewer than ten, so there is no comparison to draw.
3 of the studies in Lymphohistiocytosis, Hemophagocytic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01962415Paul SzabolcsReduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT | 2026-11 |
| NCT03827343National Cancer Institute (NCI)Retrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With Cancer | 2026-12-31 |
| NCT05277272Children's Hospital Medical Center, CincinnatiINTO-HLH: A Disease Registry for Patients With Hemophagocytic Lymphohistiocytosis (HLH) | 2027-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 42 studies in Lymphohistiocytosis, Hemophagocytic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This observational study is designed to determine the levels of pro-inflammatory markers in patients diagnosed with M-HLH, and to assess whether the cytokine profiles bear an IFNγ signature.
This is a observational study designed to determine the levels of inflammatory markers in patients diagnosed with M-HLH and to assess the relationship between the biomarkers and disease activity in these patients during the M-HLH course. Inflammatory markers will also be measured in a group of control patients diagnosed with hematological malignancy but without HLH. Inflammatory markers include IFNγ and IFNγ-induced chemokines CXCL9 and CXCL10.
In addition to the blood samples for the biomarker analysis, relevant information gathered by the treating physician will be collected in a data collection form. Whenever possible, collection of serum samples for biomarker analysis and relevant information should occur at M-HLH diagnosis, at regular time intervals during the treatment course as well as at resolution or reactivation of the disease.
Blood samples will also be sent to the study sponsor (NovImmune S.A.) for cytokine testing. Before participant's samples are sent to the sponsor for testing, participant's name and any personal identifying information will be coded to protect participant's privacy.
Male and female (adult and children) patients who are diagnosed with M-HLH and that meet the inclusion criteria. In addition, patients with a diagnosis of hematological malignancy in the absence of HLH will be included as a control group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
N/A
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients diagnosed with HLH in the context of a malignancy. The diagnosis of M-HLH was established by the treating physician.
Other: Blood Draws · Other: Data Collection
Patients with a diagnosis of hematological malignancy and never diagnosed with HLH or no suspicion of HLH (at any time, including time after sample collection in case of use of retrospective sample).
Other: Blood Draws · Other: Data Collection
Mean Serum Concentration of Inflammatory Biomarker - C-X-C Chemokine Ligand 10 (CXCL10)
Serum samples was collected at various times after HLH diagnosis to determine the concentration of CXCL10.
Time frame: From Day 1 up to 39.5 months
Mean Serum Concentration of Inflammatory Biomarker - C-X-C Chemokine Ligand 9 (CXCL9)
Serum samples was collected at various times after HLH diagnosis to determine the concentration of CXCL9.
Time frame: From Day 1 up to 39.5 months
Mean Serum Concentration of Inflammatory Biomarker - Interferon Gamma (IFNg)
Serum samples was collected at various times after HLH diagnosis to determine the concentration of IFNg.
Time frame: From Day 1 up to 39.5 months
Mean Serum Concentration of Inflammatory Biomarker - Interleukin 10 (IL-10)
Serum samples was collected at various times after HLH diagnosis to determine the concentration of IL-10.
Time frame: From Day 1 up to 39.5 months
Mean Serum Concentration of Inflammatory Biomarker - Interleukin 1 Beta (IL-1B)
Serum samples was collected at various times after HLH diagnosis to determine the concentration of IL-1B.
Time frame: From Day 1 up to 39.5 months
Mean Serum Concentration of Inflammatory Biomarker - Interleukin 6 (IL-6)
Serum samples was collected at various times after HLH diagnosis to determine the concentration of IL-6.
Time frame: From Day 1 up to 39.5 months
Mean Serum Concentration of Inflammatory Biomarker - Neopterin
Serum samples was collected at various times after HLH diagnosis to determine the concentration of neopterin.
Time frame: From Day 1 up to 39.5 months
Mean Serum Concentration of Inflammatory Biomarker - Tumor Necrosis Factor Alpha (TNFa)
Serum samples was collected at various times after HLH diagnosis to determine the concentration of TNFa.
Time frame: From Day 1 up to 39.5 months
Mean Serum Concentration of Inflammatory Biomarker - Total Human Interferon Gamma (hIFNg)
Serum samples was collected at various times after HLH diagnosis to determine the concentration of hIFNg.
Time frame: From Day 1 up to 39.5 months
Mean Serum Concentration of Inflammatory Biomarker - Soluble CD163 (sCD163)
Serum samples was collected at various times after HLH diagnosis to determine the concentration of sCD163.
Time frame: From Day 1 up to 39.5 months
Mean Serum Concentration of Inflammatory Biomarker - Soluble IL-2 Receptor Alpha (sIL2Ra)
Serum samples was collected at various times after HLH diagnosis to determine the concentration of sIL2Ra.
Time frame: From Day 1 up to 39.5 months
Mean Serum Concentration of Hemoglobin
Blood samples was collected at various times after HLH diagnosis to determine the concentration of hemoglobin.
Time frame: From Day 1 up to 39.5 months
Mean Serum Concentration of Hematocrit
Blood samples was collected at various times after HLH diagnosis to determine the concentration of hematocrit.
Time frame: From Day 1 up to 39.5 months
Mean Serum Concentration of Erythrocytes
Blood samples was collected at various times after HLH diagnosis to determine the concentration of erythrocytes.
Time frame: From Day 1 up to 39.5 months
Mean Serum Concentration of Leukocytes
Blood samples was collected at various times after HLH diagnosis to determine the concentration of leukocytes.
Time frame: From Day 1 up to 39.5 months
Mean Serum Concentration of Neutrophils
Blood samples was collected at various times after HLH diagnosis to determine the concentration of neutrophils.
Time frame: From Day 1 up to 39.5 months
Mean Serum Concentration of Lymphocytes
Blood samples was collected at various times after HLH diagnosis to determine the concentration of lymphocytes.
Time frame: From Day 1 up to 39.5 months
Mean Serum Concentration of Monocytes
Blood samples was collected at various times after HLH diagnosis to determine the concentration of monocytes.
Time frame: From Day 1 up to 39.5 months
Mean Serum Concentration of Eosinophils
Blood samples was collected at various times after HLH diagnosis to determine the concentration of eosinophils.
Time frame: From Day 1 up to 39.5 months
Mean Serum Concentration of Basophils
Blood samples was collected at various times after HLH diagnosis to determine the concentration of basophils.
Time frame: From Day 1 up to 39.5 months
Mean Serum Concentration of Platelets
Blood samples was collected at various times after HLH diagnosis to determine the concentration of platelets.
Time frame: From Day 1 up to 39.5 months
Mean Plasma Concentration of Fibrinogen
Blood samples was collected at various times after HLH diagnosis to determine the concentration of fibrinogen.
Time frame: From Day 1 up to 39.5 months
Mean Plasma Concentration of D-Dimer
Blood samples was collected at various times after HLH diagnosis to determine the concentration of D-dimer.
Time frame: From Day 1 up to 39.5 months
Mean Serum Concentration of Ferritin
Blood samples was collected at various times after HLH diagnosis to determine the concentration of ferritin.
Time frame: From Day 1 up to 39.5 months
Mean Serum Concentration of Fasting Triglycerides
Blood samples was collected at various times after HLH diagnosis to determine the concentration of fasting triglycerides.
Time frame: From Day 1 up to 39.5 months
Mean Serum Concentration of Creatinine
Blood samples was collected at various times after HLH diagnosis to determine the concentration of creatinine.
Time frame: From Day 1 up to 39.5 months
Mean Plasma Concentration of Blood Urea Nitrogen
Blood samples was collected at various times after HLH diagnosis to determine the concentration of blood urea nitrogen.
Time frame: From Day 1 up to 39.5 months
Mean Serum Concentration of Albumin
Blood samples was collected at various times after HLH diagnosis to determine the concentration of albumin.
Time frame: From Day 1 up to 39.5 months
Mean Serum Concentration of Sodium
Blood samples was collected at various times after HLH diagnosis to determine the concentration of sodium.
Time frame: From Day 1 up to 39.5 months
Mean Serum Concentration of Beta2-Microglobulin
Blood samples was collected at various times after HLH diagnosis to determine the concentration of beta2-microglobulin.
Time frame: From Day 1 up to 39.5 months
Mean Serum Concentration of Immunoglobulin G (IgG)
Blood samples was collected at various times after HLH diagnosis to determine the concentration of IgG.
Time frame: From Day 1 up to 39.5 months
Mean Serum Concentration of C-Reactive Protein
Blood samples was collected at various times after HLH diagnosis to determine the concentration of c-reactive protein.
Time frame: From Day 1 up to 39.5 months
Mean Serum Concentration of Aspartate Aminotransferase
Blood samples was collected at various times after HLH diagnosis to determine the concentration of aspartate aminotransferase.
Time frame: From Day 1 up to 39.5 months
Mean Serum Concentration of Alanine Aminotransferase
Blood samples was collected at various times after HLH diagnosis to determine the concentration of alanine aminotransferase.
Time frame: From Day 1 up to 39.5 months
Mean Serum Concentration of Alkaline Phosphatase
Blood samples was collected at various times after HLH diagnosis to determine the concentration of alkaline phosphatase.
Time frame: From Day 1 up to 39.5 months
Mean Serum Concentration of Lactate Dehydrogenase
Blood samples was collected at various times after HLH diagnosis to determine the concentration of lactate dehydrogenase.
Time frame: From Day 1 up to 39.5 months
Mean Serum Concentration of Total Bilirubin
Blood samples was collected at various times after HLH diagnosis to determine the concentration of total bilirubin.
Time frame: From Day 1 up to 39.5 months
Mean Serum Concentration of Conjugated Bilirubin
Blood samples was collected at various times after HLH diagnosis to determine the concentration of conjugated bilirubin.
Time frame: From Day 1 up to 39.5 months
Mean Serum Concentration of Natural Killer (NK) Cell Activity
Blood samples was collected at various times after HLH diagnosis to determine the concentration of NK cell activity. A lytic unit 30 (LU30) was defined as the number of effector cells necessary to cause lysis of 30% of its target cells.
Time frame: From Day 1 up to 39.5 months
This Phase 4 observational study was conducted in patients diagnosed with malignancy-associated hemophagocytic lymphohistiocytosis (M-HLH) at a single center in the United States of America.
| Milestone | Hemophagocytic Lymphohistiocytosis (HLH) Patients | Non-HLH Patients |
|---|---|---|
| Started | 20 | 20 |
| Malignancy analysis set | 19 | 20 |
| Completed | 19 | 20 |
| Not completed | 1 | 0 |
| Withdrew: Excluded from the malignancy analysis set | 1 | 0 |
Serum samples was collected at various times after HLH diagnosis to determine the concentration of CXCL10.
| picogram/milliliter (pg/mL) | HLH Patients | Non-HLH Patients |
|---|---|---|
| Mean Serum Concentration of Inflammatory Biomarker - C-X-C Chemokine Ligand 10 (CXCL10) | 5040.638 ± 9622.745 | 454.392 ± 246.307 |
Serum samples was collected at various times after HLH diagnosis to determine the concentration of CXCL9.
| pg/mL | HLH Patients | Non-HLH Patients |
|---|---|---|
| Mean Serum Concentration of Inflammatory Biomarker - C-X-C Chemokine Ligand 9 (CXCL9) | 8878.698 ± 17582.571 | 1864.255 ± 4986.931 |
Serum samples was collected at various times after HLH diagnosis to determine the concentration of IFNg.
| pg/mL | HLH Patients | Non-HLH Patients |
|---|---|---|
| Mean Serum Concentration of Inflammatory Biomarker - Interferon Gamma (IFNg) | 279.951 ± 898.740 | 8.014 ± 2.370 |
Serum samples was collected at various times after HLH diagnosis to determine the concentration of IL-10.
| pg/mL | HLH Patients | Non-HLH Patients |
|---|---|---|
| Mean Serum Concentration of Inflammatory Biomarker - Interleukin 10 (IL-10) | 46.562 ± 124.537 | 2.185 ± 2.953 |
Serum samples was collected at various times after HLH diagnosis to determine the concentration of IL-1B.
| pg/mL | HLH Patients | Non-HLH Patients |
|---|---|---|
| Mean Serum Concentration of Inflammatory Biomarker - Interleukin 1 Beta (IL-1B) | 2.140 ± 0.000 | 2.140 ± 0.000 |
Serum samples was collected at various times after HLH diagnosis to determine the concentration of IL-6.
| pg/mL | HLH Patients | Non-HLH Patients |
|---|---|---|
| Mean Serum Concentration of Inflammatory Biomarker - Interleukin 6 (IL-6) | 597.385 ± 1776.853 | 10.059 ± 28.771 |
Serum samples was collected at various times after HLH diagnosis to determine the concentration of neopterin.
| nanomoles | HLH Patients | Non-HLH Patients |
|---|---|---|
| Mean Serum Concentration of Inflammatory Biomarker - Neopterin | 257.120 ± 223.475 | 51.909 ± 47.869 |
Serum samples was collected at various times after HLH diagnosis to determine the concentration of TNFa.
| pg/mL | HLH Patients | Non-HLH Patients |
|---|---|---|
| Mean Serum Concentration of Inflammatory Biomarker - Tumor Necrosis Factor Alpha (TNFa) | 12.412 ± 14.899 | 4.751 ± 4.054 |
Serum samples was collected at various times after HLH diagnosis to determine the concentration of hIFNg.
| pg/mL | HLH Patients | Non-HLH Patients |
|---|---|---|
| Mean Serum Concentration of Inflammatory Biomarker - Total Human Interferon Gamma (hIFNg) | 82.227 ± 196.240 | 417.603 ± 1573.368 |
Serum samples was collected at various times after HLH diagnosis to determine the concentration of sCD163.
| nanogram/mL | HLH Patients | Non-HLH Patients |
|---|---|---|
| Mean Serum Concentration of Inflammatory Biomarker - Soluble CD163 (sCD163) | 3796.175 ± 3154.561 | 1812.384 ± 2852.523 |
Serum samples was collected at various times after HLH diagnosis to determine the concentration of sIL2Ra.
| pg/mL | HLH Patients | Non-HLH Patients |
|---|---|---|
| Mean Serum Concentration of Inflammatory Biomarker - Soluble IL-2 Receptor Alpha (sIL2Ra) | 10183.509 ± 12244.564 | 2575.569 ± 3395.536 |
Blood samples was collected at various times after HLH diagnosis to determine the concentration of hemoglobin.
| gram/deciliter (g/dL) | HLH Patients | Non-HLH Patients |
|---|---|---|
| Mean Serum Concentration of Hemoglobin | 9.31 ± 0.98 | 8.52 ± 1.95 |
Blood samples was collected at various times after HLH diagnosis to determine the concentration of hematocrit.
| liter (L) of cells/L of blood | HLH Patients | Non-HLH Patients |
|---|---|---|
| Mean Serum Concentration of Hematocrit | 27.28 ± 3.41 | 25.94 ± 4.99 |
Blood samples was collected at various times after HLH diagnosis to determine the concentration of erythrocytes.
| cells*10^12/L | HLH Patients | Non-HLH Patients |
|---|---|---|
| Mean Serum Concentration of Erythrocytes | 3.208 ± 0.371 | 2.896 ± 0.543 |
Blood samples was collected at various times after HLH diagnosis to determine the concentration of leukocytes.
| cells*10^9/L | HLH Patients | Non-HLH Patients |
|---|---|---|
| Mean Serum Concentration of Leukocytes | 2.11 ± 2.85 | 8.42 ± 8.94 |
Blood samples was collected at various times after HLH diagnosis to determine the concentration of neutrophils.
| cells*10^3/microliter (mcL) | HLH Patients | Non-HLH Patients |
|---|---|---|
| Mean Serum Concentration of Neutrophils | 1.743 ± 2.550 | 1.984 ± 1.776 |
Blood samples was collected at various times after HLH diagnosis to determine the concentration of lymphocytes.
| cells*10^3/mcL | HLH Patients | Non-HLH Patients |
|---|---|---|
| Mean Serum Concentration of Lymphocytes | 0.468 ± 0.647 | 0.968 ± 1.084 |
Blood samples was collected at various times after HLH diagnosis to determine the concentration of monocytes.
| cells*10^3/mcL | HLH Patients | Non-HLH Patients |
|---|---|---|
| Mean Serum Concentration of Monocytes | 0.233 ± 0.272 | 1.278 ± 1.034 |
Blood samples was collected at various times after HLH diagnosis to determine the concentration of eosinophils.
| cells*10^3/mcL | HLH Patients | Non-HLH Patients |
|---|---|---|
| Mean Serum Concentration of Eosinophils | 0.032 ± 0.044 | 1.083 ± 1.441 |
Blood samples was collected at various times after HLH diagnosis to determine the concentration of basophils.
| cells*10^3/mcL | HLH Patients | Non-HLH Patients |
|---|---|---|
| Mean Serum Concentration of Basophils | 0.100 ± 0.087 | 0.820 ± 0.834 |
Blood samples was collected at various times after HLH diagnosis to determine the concentration of platelets.
| cells*10^3/mcL | HLH Patients | Non-HLH Patients |
|---|---|---|
| Mean Serum Concentration of Platelets | 43.9 ± 67.7 | 30.8 ± 38.5 |
Blood samples was collected at various times after HLH diagnosis to determine the concentration of fibrinogen.
| milligram (mg)/dL | HLH Patients | Non-HLH Patients |
|---|---|---|
| Mean Plasma Concentration of Fibrinogen | 207.5 ± 143.0 | 357.5 ± 2.1 |
Blood samples was collected at various times after HLH diagnosis to determine the concentration of D-dimer.
| microgram (mcg)/mL | HLH Patients | Non-HLH Patients |
|---|---|---|
| Mean Plasma Concentration of D-Dimer | 10.165 ± 7.569 | 2.220 ± 2.107 |
Blood samples was collected at various times after HLH diagnosis to determine the concentration of ferritin.
| mcg/L | HLH Patients | Non-HLH Patients |
|---|---|---|
| Mean Serum Concentration of Ferritin | 17240.3470 ± 30134.8903 | 3.8940 ± 4.1748 |
Blood samples was collected at various times after HLH diagnosis to determine the concentration of fasting triglycerides.
| mg/dL | HLH Patients | Non-HLH Patients |
|---|---|---|
| Mean Serum Concentration of Fasting Triglycerides | 231.5 ± 88.6 | — |
Blood samples was collected at various times after HLH diagnosis to determine the concentration of creatinine.
| mg/dL | HLH Patients | Non-HLH Patients |
|---|---|---|
| Mean Serum Concentration of Creatinine | 1.682 ± 2.726 | 0.808 ± 0.287 |
Blood samples was collected at various times after HLH diagnosis to determine the concentration of blood urea nitrogen.
| mg/dL | HLH Patients | Non-HLH Patients |
|---|---|---|
| Mean Plasma Concentration of Blood Urea Nitrogen | 44.68 ± 30.53 | 29.00 ± 3.92 |
Blood samples was collected at various times after HLH diagnosis to determine the concentration of albumin.
| g/dL | HLH Patients | Non-HLH Patients |
|---|---|---|
| Mean Serum Concentration of Albumin | 2.88 ± 0.60 | 3.48 ± 0.82 |
Blood samples was collected at various times after HLH diagnosis to determine the concentration of sodium.
| millimoles/L | HLH Patients | Non-HLH Patients |
|---|---|---|
| Mean Serum Concentration of Sodium | 137.3 ± 7.4 | 139.5 ± 4.1 |
Blood samples was collected at various times after HLH diagnosis to determine the concentration of beta2-microglobulin.
| mg/L | HLH Patients | Non-HLH Patients |
|---|---|---|
| Mean Serum Concentration of Beta2-Microglobulin | 9.48 ± 15.19 | 3.10 ± NA |
Blood samples was collected at various times after HLH diagnosis to determine the concentration of IgG.
| mg/dL | HLH Patients | Non-HLH Patients |
|---|---|---|
| Mean Serum Concentration of Immunoglobulin G (IgG) | 602.2 ± 250.6 | 722.0 ± 353.6 |
Blood samples was collected at various times after HLH diagnosis to determine the concentration of c-reactive protein.
| mg/dL | HLH Patients | Non-HLH Patients |
|---|---|---|
| Mean Serum Concentration of C-Reactive Protein | 102.508 ± 174.824 | — |
Blood samples was collected at various times after HLH diagnosis to determine the concentration of aspartate aminotransferase.
| international units/L (IU/L) | HLH Patients | Non-HLH Patients |
|---|---|---|
| Mean Serum Concentration of Aspartate Aminotransferase | 177.8 ± 279.9 | 44.8 ± 18.4 |
Blood samples was collected at various times after HLH diagnosis to determine the concentration of alanine aminotransferase.
| IU/L | HLH Patients | Non-HLH Patients |
|---|---|---|
| Mean Serum Concentration of Alanine Aminotransferase | 127.9 ± 179.0 | 34.0 ± 25.4 |
Blood samples was collected at various times after HLH diagnosis to determine the concentration of alkaline phosphatase.
| IU/L | HLH Patients | Non-HLH Patients |
|---|---|---|
| Mean Serum Concentration of Alkaline Phosphatase | 216.0 ± 170.5 | 95.0 ± 74.5 |
Blood samples was collected at various times after HLH diagnosis to determine the concentration of lactate dehydrogenase.
| IU/L | HLH Patients | Non-HLH Patients |
|---|---|---|
| Mean Serum Concentration of Lactate Dehydrogenase | 7469.5 ± 10456.7 | 1100.8 ± 718.5 |
Blood samples was collected at various times after HLH diagnosis to determine the concentration of total bilirubin.
| mg/dL | HLH Patients | Non-HLH Patients |
|---|---|---|
| Mean Serum Concentration of Total Bilirubin | 2.64 ± 3.85 | 1.68 ± 1.40 |
Blood samples was collected at various times after HLH diagnosis to determine the concentration of conjugated bilirubin.
| mg/dL | HLH Patients | Non-HLH Patients |
|---|---|---|
| Mean Serum Concentration of Conjugated Bilirubin | 1.96 ± 3.71 | 0.00 ± NA |
Blood samples was collected at various times after HLH diagnosis to determine the concentration of NK cell activity. A lytic unit 30 (LU30) was defined as the number of effector cells necessary to cause lysis of 30% of its target cells.
| LU30 | HLH Patients | Non-HLH Patients |
|---|---|---|
| Mean Serum Concentration of Natural Killer (NK) Cell Activity | 3.5 ± 0.7 | — |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| HLH Patients | — | — | — |
| Non-HLH Patients | — | — | — |
The malignancy set included all patients who were diagnosed with malignancy.
| Age, Continuous(years) | HLH Patients | Non-HLH Patients | Total |
|---|---|---|---|
| Mean | 56.7 ± 18.6 | 63.2 ± 15.3 | 60.0 ± 17.1 |
| Sex: Female, Male(Participants) | HLH Patients | Non-HLH Patients | Total |
|---|---|---|---|
| Female | 4 | 8 | 12 |
| Male | 15 | 12 | 27 |
| Race and Ethnicity Not Collected(Participants) | HLH Patients | Non-HLH Patients | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2016 to primary completion in Jan 2020, 39 months.
Results were first posted in Sep 2024, 4 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lymphohistiocytosis, Hemophagocytic →